Patents Examined by Ilia Ouspenski
  • Patent number: 10098934
    Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants awhich are suitable targets for immunotherapy, cancer therapy, and drug development.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: October 16, 2018
    Assignee: COMPUGEN LTD
    Inventors: Zurit Levine, Amir Toporik, Amit Novik, Anat Cohen-Dayag, Avi Rosenberg, Cynthia Koifman, Dalit Landesman-Milo, Eve Montia, Galit Rotman, Liat Dassa, Marina Bubis, Merav Beiman, Ofer Levy, Sergey Nemzer, Shira Walach, Shirley Sameach- Greenwald, Tania Pergam, Yaron Kinar
  • Patent number: 9957312
    Abstract: Fusion proteins containing B7-H4 polypeptides are disclosed. The B7-H4 fusion proteins can include full-length B7-H4 polypeptides, or can contain a fragment of a full-length B7-H4 polypeptide, including some or all of the extracellular domain of the B7-H4 polypeptide. Methods for using the fusion proteins to downregulate T cell activation and for the treatment of inflammatory and autoimmune diseases and disorders are also disclosed. The B7-H4 fusion proteins are useful for treating inflammation by inhibiting or reducing differentiation, proliferation, activity, and/or cytokine production and/or secretion by ThI, ThI 7, Th22, and/or other cells that secrete, or cause other cells to secrete, inflammatory molecules, including, but not limited to, IL-1?, TNF-?, TGF-beta, IFN-?, IL-17, IL-6, IL-23, IL-22, IL-21, and MMPs; or enhancing IL-IO secretion by Tregs, increasing the differentiation of Tregs, increasing the number of Tregs, or combinations thereof.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: May 1, 2018
    Assignee: MedImmune, LLC
    Inventors: Solomon Langermann, Linda Liu, Joseph R. Podojil, Stephen D. Miller, Shannon Marshall
  • Patent number: 9944689
    Abstract: Mutant forms of human CTLA4, and their use, e.g., in xenotransplantation.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: April 17, 2018
    Assignee: The General Hospital Corporation
    Inventors: Zhirui Wang, Christene A. Huang, David H. Sachs
  • Patent number: 9944690
    Abstract: The technology relates generally to the field of immunology and relates in part to compositions and methods for controlling the proliferation of T cells, for example, therapeutic T cells. The methods further relate to compositions and methods for inducing an immune response in a subject.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: April 17, 2018
    Inventors: David Spencer, Aaron Edward Foster, Kevin Slawin
  • Patent number: 9908937
    Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: March 6, 2018
    Assignees: Bristol-Myers Squibb Company, Domantis Limited
    Inventors: Murray McKinnon, Steven G. Nadler, Suzanne J. Suchard, Brendan Classon, Steve Holmes, Olga Ignatovich, Christopher Plummer, Steve Grant
  • Patent number: 9896507
    Abstract: The invention relates to BTLA antibodies that block BTLA-HVEM interaction and uses thereof.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: February 20, 2018
    Assignees: Université d'Aix Marseille, INSERM (Institut National de la Santé et de la Recherche Médicale)
    Inventors: Daniel Olive, Francoise Gondois-Rey, Nacer-Eddine Serriari, Sonia Pastor
  • Patent number: 9890215
    Abstract: The present disclosure relates to compositions and therapeutic methods for activating an immune response in a patient in need thereof. In a preferred embodiment, the subject methods and compositions are able to antagonize the activity of VISTA, a naturally occurring “checkpoint” protein which contributes to immune tolerance, optionally in combination with an antagonist of a second checkpoint pathway such as PD-1. For example, such methods and compositions may be suitable for preventing and treating colon cancer or another cancer. An exemplary VISTA antagonist, specifically, an anti-VISTA antibody, is demonstrated herein to activate an immune response against cancer cells in vitro and in vivo, thereby conferring protective anti-tumor immunity which decreased tumor burden. Additionally, an additive benefit was observed when a VISTA antagonist was used in combination with a second checkpoint protein antagonist, specifically, an antibody against PD-1 ligand (PD-L1).
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: February 13, 2018
    Inventor: Randolph J. Noelle
  • Patent number: 9884903
    Abstract: B7-H5 costimulatory polypeptides, nucleic acids encoding such polypeptides, and methods for using the polypeptides and nucleic acids to enhance a T cell response are provided herein.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: February 6, 2018
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Lieping Chen
  • Patent number: 9873744
    Abstract: T cell memory can persist in the absence of antigen. However, some memory cells by default are subject to signals accompanying periodic antigen exposure. OX40 is essential to the extent and persistence of Th2 memory when antigen is re-encountered. In an animal model of allergic asthma, inhibiting OX40/OX40L signaling during the secondary response to inhaled antigen suppressed lung inflammation. Inhibiting OX40 at the time of memory cell reactivation reduced the longevity of memory with further inflammation prevented upon tertiary encounter with antigen.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: January 23, 2018
    Inventors: Michael Croft, Shahram Salek-Ardakani
  • Patent number: 9873740
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: January 23, 2018
    Assignee: Genentech, Inc.
    Inventors: Jane Grogan, Robert J. Johnston, Bryan Irving, Jason Hackney, Xin Yu, Dan Eaton, Kristin Bowles, Laetitia Comps-Agrar
  • Patent number: 9868961
    Abstract: The present invention provides compositions and methods for effectuating the localized expression of anti-CTLA-4 antibody proximal to a target tissue in a patient.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: January 16, 2018
    Assignee: The Regents of the University of California
    Inventors: James Allison, Michael Curran
  • Patent number: 9868789
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: January 16, 2018
    Assignee: Kymab Limited
    Inventors: Philip Bland-Ward, Miha Kosmac, Steve Holmes, Ian Kirby, Jamie Campbell
  • Patent number: 9856318
    Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: January 2, 2018
    Assignee: Yeda Research and Development Co., Ltd.
    Inventors: Michal Eisenbach-Schwartz, Kuti Baruch, Neta Rosenzweig
  • Patent number: 9856320
    Abstract: The disclosure provides a method for immunotherapy of a cancer patient, comprises administering to the patient an Ab that inhibits signaling from the PD-1/PD-L1 signaling pathway, or a combination of such Ab and an anti-CTLA-4 Ab. This disclosure also provides a method for immunotherapy of a cancer patient comprising selecting a patient who is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the patient that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering an anti-PD-1 Ab to the selected subject. The disclosure additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: January 2, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: John P. Cogswell, Stacie M. Goldberg, Ashok Kumar Gupta, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton
  • Patent number: 9856322
    Abstract: The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the 4-1BB signaling domain. Embodiments of the invention relate to polynucleotides that encode the receptor, vectors and host cells encoding a chimeric receptor, particularly including T cells and natural killer (NK) cells and methods of use.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: January 2, 2018
    Assignee: St Jude Children's Research Hospital, Inc.
    Inventors: Dario Campana, Chihaya Imai
  • Patent number: 9840562
    Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: December 12, 2017
    Assignees: Bristol-Myers Squibb Company, Pfizer Inc.
    Inventors: Jing Min, Yanli Wu, Rory F. Finn, Barrett R. Thiele, Wei Liao, Ronald P. Gladue, Arvind Rajpal, Timothy J. Paradis, Peter Brams, Brigitte Devaux, Yi Wu, Kristopher Toy, Heidi N. LeBlanc, Haichun Huang
  • Patent number: 9833480
    Abstract: The invention features nucleic acid constructs encoding chimeric immune T-cell receptors (CIRs) that are useful for treating HIV in patients. In general, the CIRs contain an extracellular domain which targets HIV or HIV infected cells (e.g., the extracellular domain of CD4), a transmembrane domain, and a cytoplasmic domain for mediating T-cell activation (e.g., CD3 zeta and/or the partial extracellular domain of CD28). The invention also features the use of host cells expressing CIRs in the treatment of HIV.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: December 5, 2017
    Assignee: Prospect Chartercare, LLC
    Inventors: Richard P. Junghans, Nithianandan Selliah
  • Patent number: 9834606
    Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: December 5, 2017
    Assignee: BEIGENE, LTD
    Inventors: Kang Li, Tong Zhang, Jing Song, Lanlan Xu, Qi Liu, Hao Peng
  • Patent number: 9834605
    Abstract: Antibodies which block binding of hPD-1 to hPD-L1 or hPD-L2 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the PD-1 pathway is also disclosed.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: December 5, 2017
    Assignee: Merck Sharpe & Dohme B.V.
    Inventors: Gregory John Carven, Hans Van Eenenneem, Gradus Johannes Dulos
  • Patent number: 9834611
    Abstract: The present invention relates to immunoglobulin single variable domain sequences that are directed against (as defined herein) OX40L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such immunoglobulin single variable domain sequences. In particular these immunoglobulin single variable domain sequences can block binding of OX40L to OX40. The immunoglobulin single variable domains, compounds and constructs can be used for prophylactic, therapeutic or diagnostic purposes, such as for the treatment of inflammatory disease and/or disorder such as e.g. asthma, allergic asthma, chronic colitis, Crohn's disease, inflammatory bowel disease, and/or arthrosclerosis.
    Type: Grant
    Filed: December 31, 2014
    Date of Patent: December 5, 2017
    Assignee: Ablynx N.V.
    Inventors: Frank Verdonck, Sigrid Cornelis, Stephanie Staelens